| abstract |
The present invention provides an agent comprising heparin-binding EGF-like growth factor (HB-EGF), or a functional fragment, variant or derivative thereof, for use in the prevention and/or treatment of skin blistering. Also provided are compositions comprising the agent, nucleic acids and expression vectors encoding the agent, and a method of treating skin blistering using the agent. |